Cargando…

Expression of IDO1 and PD-L2 in Patients with Benign Lymphadenopathies and Association with Autoimmune Diseases

The expression patterns of IDO1 and PD-L2 have not been thoroughly investigated in benign lymphadenopathies. The aim with this study was to elucidate how IDO1 and PD-L2 are expressed in benign lymphadenopathies in patients with autoimmune diseases (AD) compared to patients without AD. Formalin-fixed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdulla, Maysaa, Sundström, Christer, Lindskog, Cecilia, Hollander, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952948/ https://www.ncbi.nlm.nih.gov/pubmed/36830609 http://dx.doi.org/10.3390/biom13020240

Ejemplares similares

Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases—A Possible Association with High Rheumatoid Arthritis Disease Activity
por: Hellbacher, Erik, et al.
Publicado: (2022)

IDO2 in Immunomodulation and Autoimmune Disease
por: Prendergast, George C., et al.
Publicado: (2014)

High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients
por: Ludovini, Vienna, et al.
Publicado: (2021)

IL-27 induces the expression of IDO and PD-L1 in human cancer cells
por: Carbotti, Grazia, et al.
Publicado: (2015)

Tolerogenic IDO(+) Dendritic Cells Are Induced by PD-1-Expressing Mast Cells
por: Rodrigues, Cecilia Pessoa, et al.
Publicado: (2016)

Expression of immune checkpoints (PD-L1 and IDO) and tumour-infiltrating lymphocytes in breast cancer
por: Alkhayyal, Noura, et al.
Publicado: (2022)

Risk analysis in persistent cervical lymphadenopathies: Malignant or benign?
por: Metin, Ulas, et al.
Publicado: (2021)

Handling benign interlobar lymphadenopathy during thoracoscopic lobectomy
por: Fiorelli, Alfonso, et al.
Publicado: (2021)

IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity
por: Merlo, Lauren M.F., et al.
Publicado: (2016)

Castleman disease, TAFRO syndrome, idiopathic plasmacytic lymphadenopathy, and autoimmune disease
por: Nakamura, Naoya
Publicado: (2022)

Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes
por: Pallotta, Maria Teresa, et al.
Publicado: (2014)

IgG4‐related lymphadenopathy: Benign but with rare recurrent
por: Song, Kevin, et al.
Publicado: (2021)

Superinduction of immunosuppressive glioblastoma extracellular vesicles by IFN-γ through PD-L1 and IDO1
por: Jung, Mi-Yeon, et al.
Publicado: (2022)

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
por: Della Corte, Carminia Maria, et al.
Publicado: (2022)

Unexplained lymphadenopathies: autoimmune lymphoproliferative syndrome in an adult patient
por: Leal-Seabra, Fatima, et al.
Publicado: (2016)

Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG(35-55)-induced experimental autoimmune encephalomyelitis
por: Wetzel, Lisa A., et al.
Publicado: (2020)

Kikuchi-Fujimoto Disease: A Rare Benign Cause of Lymphadenopathy That Mimics Malignant Lymphoma
por: Gism Elseed, Israa, et al.
Publicado: (2022)

Benign reactive lymphadenopathy associated with submandibular gland enlargement during orthodontic treatment
por: Pulgaonkar, Rohan, et al.
Publicado: (2017)

PD-L1 is Fascinating but IDO Needs Attention in Non-HCV and Non-HBV-Associated Hepatocellular Carcinoma Patients
por: Asghar, Kashif, et al.
Publicado: (2023)

IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity
por: Lippens, Carla, et al.
Publicado: (2016)

Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance
por: Moon, Peter Kim, et al.
Publicado: (2019)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

A Girl with Autoimmune Cytopenias, Nonmalignant Lymphadenopathy, and Recurrent Infections
por: Mattheij, Marjolein A. C., et al.
Publicado: (2012)

Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma
por: Hollander, Peter, et al.
Publicado: (2018)

IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
por: Amobi-McCloud, Adaobi, et al.
Publicado: (2021)

Lymphadenopathy and Diseases of the Spleen
por: Lanzkowsky, Philip
Publicado: (2016)

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2023)

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
por: Botticelli, Andrea, et al.
Publicado: (2018)

Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma
por: Thummalapalli, Rohit, et al.
Publicado: (2020)

Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways
por: Xiang, Zhen, et al.
Publicado: (2021)

IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells
por: Nawas, Afshan Fathima, et al.
Publicado: (2023)

Apparent Diffusion Coefficient Measurement in Mediastinal Lymphadenopathies: Differentiation between Benign and Malignant Lesions
por: Ustabasioglu, Fethi Emre, et al.
Publicado: (2017)

Can magnetic resonance spectroscopy differentiate malignant and benign causes of lymphadenopathy? An in-vitro approach
por: Buré, Lionel, et al.
Publicado: (2017)

Evaluation of Acoustic Radiation Force Impulse Imaging in Differentiating Benign and Malignant Cervical Lymphadenopathy
por: Rohan, Kamat, et al.
Publicado: (2021)

Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022)

Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2013)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome
por: Hu, Chuan, et al.
Publicado: (2023)

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020)

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p9ucbdjaacl1bp23l5egfcqstq